Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C

Nature Reviews Gastroenterology and Hepatology

Volumn 8, Issue 4, 2011, Pages 212-223

  Sulkowski, Mark S ^a   Cooper, Curtis ^b   Hunyady, Bela ^c   Jia, Jidong ^d   Ogurtsov, Pavel ^e   Peck Radosavljevic, Markus ^f   Shiffman, Mitchell L ^g   Yurdaydin, Cihan ^h   Dalgard, Olav ⁱ  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF OTTAWA   (Canada)

^c Kaposi Mor Teaching Hospital   (Hungary)

^d CAPITAL MEDICAL UNIVERSITY   (China)

^e PEOPLES FRIENDSHIP UNIVERSITY OF RUSSIA   (Russian Federation)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

^g Bon Secours Virginia Health System   (United States)

^h ANKARA UNIVERSITY   (Turkey)

ⁱ AKERSHUS UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOTRIMAZOLE; CORTICOSTEROID; ELTROMBOPAG; KETOCONAZOLE; LEVOTHYROXINE; METHYLPHENIDATE; METOCLOPRAMIDE; MINOXIDIL; MODAFINIL; MOOD STABILIZER; NEUROLEPTIC AGENT; NORADRENALIN UPTAKE INHIBITOR; ONDANSETRON; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2B; PROCHLORPERAZINE; PROMETHAZINE; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN; SEDATIVE AGENT; SEROTONIN UPTAKE INHIBITOR;

ACNE; ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ADJUVANT THERAPY; ADVERSE DRUG REACTION; ALOPECIA; ANEMIA; ANGIONEUROTIC EDEMA; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNE THYROIDITIS; BLINDNESS; BONE MARROW SUPPRESSION; BRONCHITIS; BULLOUS SKIN DISEASE; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHEMOTHERAPY INDUCED EMESIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COGNITIVE DEFECT; CONVULSION; CORNEA ULCER; COUGHING; DEPRESSION; DERMATITIS; DERMATOMYCOSIS; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DRY SKIN; DYSPNEA; ECZEMA; ERYTHEMA; ERYTHEMA MULTIFORME; EXERCISE; EYE DISEASE; FACE EDEMA; FATIGUE; FURUNCULOSIS; GASTROINTESTINAL DISEASE; GRAVES DISEASE; HAIR TEXTURE; HEMOLYSIS; HEMORRHAGIC COLITIS; HEPATITIS C; HERPES SIMPLEX; HUMAN; HYPERTHYROIDISM; HYPOMANIA; HYPOTHYROIDISM; INFECTION; INJECTION SITE ABSCESS; INJECTION SITE NECROSIS; INJECTION SITE PAIN; INJECTION SITE REACTION; INSOMNIA; INSULIN DEPENDENT DIABETES MELLITUS; INTERSTITIAL PNEUMONIA; ISCHEMIC COLITIS; LIVER CIRRHOSIS; LUNG DISEASE; LUNG SARCOIDOSIS; MACULOPAPULAR RASH; MANIA; MENTAL DISEASE; NAIL DISEASE; NAUSEA AND VOMITING; NEUTROPENIA; NIGHT SWEAT; OPTIC NERVE DISEASE; OPTIC NEURITIS; PAPILLEDEMA; PERICARDITIS; PERIPHERAL EDEMA; PHOTOSENSITIVITY; PNEUMONIA; POLYNEUROPATHY; PORPHYRIA CUTANEA TARDA; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PRURITUS; PSORIASIS; PSORIATIC ARTHRITIS; PULMONARY HYPERTENSION; RETINA ARTERY OCCLUSION; RETINA DISEASE; RETINA HEMORRHAGE; RETINA MACULA EDEMA; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SARCOIDOSIS; SIDE EFFECT; SKIN DISEASE; SKIN INFECTION; STEVENS JOHNSON SYNDROME; SUICIDAL IDEATION; SWEATING; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS; URTICARIA; VISUAL FIELD DEFECT; VISUAL IMPAIRMENT; XEROSIS;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPATITIS C; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; POLYETHYLENE GLYCOLS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 79953729036     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2011.21     Document Type: Review

References (107)

1. Deuffic, S., Poynard, T. & Valleron, A. J. Correlation between hepatitis C virus prevalence and hepatocellular carcinoma mortality in Europe. J. Viral Hepat. 6, 411-413 (1999). (Pubitemid 29470172)
2. El-Serag, H. B. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 127, S27-S34 (2004). (Pubitemid 39423367)
3. Shepard, C W., Finelli, L. & Alter, M. J. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 5, 558-567 (2005). (Pubitemid 41196755)
4. Yee, T. T. et al. The natural history of HCV in a cohort of haemophilic patients infected between 1961 and 1985. Gut 47, 845-851 (2000).
5. NIH National Institute of Health Consensus. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002\June 10-12, 2002. Hepatology 36 (Suppl. 5B), S3-S20 (2002).
6. Ghany, M. G., Strader, D. B., Thomas, D. L. & Seeff, L B. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49, 1335-1374 (2009).
7. Fried, M. W. et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347, 975-982 (2002).
8. Hadziyannis, S. J. et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 140, 346-355 (2004).
9. Manns, M. P et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358, 958-965 (2001). (Pubitemid 32913521)
10. McHutchison, J. G. et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N. Engl. J. Med. 361, 580-593 (2009).
11. Shiffman, M. L. et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N. Engl. J. Med. 357, 124-134 (2007). (Pubitemid 47057730)
12. Fattovich, G., Giustina, G., Favarato, S. & Ruol, A. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J. Hepatol. 24, 38-47 (1996).
13. McHutchison, J. G. et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C Gastroenterology 123, 1061-1069 (2002).
14. Lindsay, K. L. Therapy of hepatitis C: overview. Hepatology 26 (Suppl. 1), 547-548 (1997).
15. Soza, A. et al. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C Hepatology 36, 1273-1279 (2002). (Pubitemid 35253446)
16. Sulkowski, M. S. et al. Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection. J. Viral Hepat. 11, 243-250 (2004). (Pubitemid 38658449)
17. Valentine, A. D. & Meyers, C A. Neurobehavioral effects of interferon therapy. Curr. Psychiatry Rep. 7, 391-395 (2005). (Pubitemid 41684187)
18. Gervais, A., Boyer, N. & Marcellin, P Tolerability of treatments for viral hepatitis. Drug Safety 24, 375-384 (2001). (Pubitemid 32417536)
19. Martin, K. A., Krahn, L E., Balan, V & Rosati, M. J. Modafinil's use in combating interferon-induced fatigue. Dig. Dis. Sci. 52, 893-896 (2007). (Pubitemid 46481270)
20. Dimeo, F. C et al. Effects of physical activity on the fatigue and psychologic status of cancer patients during chemotherapy. Cancer 85, 2273-2277 (1999). (Pubitemid 29215569)
21. Aghemo, A. et al. Anemia during peginterferon-ribavirin therapy results from both increased suppression of erythroid differentiation and haemolysis [abstract 1034]. Hepatology 48, 890A-891A (2008).
22. Aslam, A. K. & Singh, T. Aplastic anemia associated with interferon beta-1a. Am. J. Ther. 9, 522-523 (2002).
23. Schmid, M. et al. Suppression of haematopoiesis during therapy of chronic hepatitis C with different interferon alpha mono and combination therapy regimens. Gut 54, 1014-1020 (2005). (Pubitemid 40873919)
24. Pegasys® (peginterferon α-2a) package insert (Roche, 2010).
25. PegIntron® (peginterferon α-2b) package insert (Schering, 2009).
26. Reddy, K. R. et al. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin. Gastroenterol. Hepatol. 5, 124-129 (2007). (Pubitemid 46096836)
27. Reddy, K. R., Nelson, D. R. & Zeuzem, S. Ribavirin: Current role in the optimal clinical management of chronic hepatitis C J. Hepatol. 50, 402-411 (2009).
28. Afdhal, N. H. et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study Gastroenterology 126, 1302-1311 (2004). (Pubitemid 38552795)
29. Falasca, K. et al. Use of epoetin beta during combination therapy of infection with hepatitis C virus with ribavirin improves a sustained viral response. J. Med. Virol. 82, 49-56 (2010).
30. Shiffman, M. L. et al. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology 46, 371-379 (2007). (Pubitemid 47344771)
31. PROCRIT® (epoetin α) package insert (Centocor Ortho Biotech Products, 2007).
32. Fellay, J. et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C Nature 464, 405-408 (2010).
33. Ochi, H. et al. ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy\a genome-wide study of Japanese HCV virus patients. Gastroenterology 139, 1190-1197 (2010).
34. Thompson, A. J. et al. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. Gastroenterology 139, 1181-1189 (2010).
35. Poordad, F et al. Hematologic safety data from the IDEAL trial: neutropenia, anemia, and thrombocytopenia profiles of peginterferon alfa/ribavirin. Presented at the 59th meeting of the AASLD.
36. Antonini, M. G. et al. Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin. Infection 36, 250-255 (2008).
37. Yang, J. F et al. Bacterial infection and neutropenia during peginterferon plus ribavirin combination therapy in patients with chronic hepatitis C with and without baseline neutropenia in clinical practice. Aliment. Pharmacol. Ther. 29, 1000-1010 (2009).
38. Roomer, R., Hansen, B. E., Janssen, H. L. & de Knegt, R. J. Thrombocytopenia and the risk of bleeding during treatment with peginterferon alfa and ribavirin for chronic hepatitis C J. Hepatol. 53, 455-459 (2010).
39. Conjeevaram, H. S. et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 131, 470-477 (2006). (Pubitemid 44142464)
40. McHutchison, J. G. et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C N. Engl. J. Med. 357, 2227-2236 (2007). (Pubitemid 350190753)
41. Afdhal, N. et al. Eltrombopag in chronic liver disease patients with thrombocytopenia undergoing an elective invasive procedure: results from ELEVATE, a randomised clinical trial. J. Hepatol. 42 (Suppl. 1), S460 (2010).
42. Kugelmas, M. & Mah'moud, M. A. Do growth factors improve SVR in chronic HCV-genotype 1 patients treated with Peg-interferon and ribavirin? Hepatology 48, 209 (2008).
43. Gallelli, L., Ferraro, M., Mauro, G. F & De Sarro, G. Generalised dermatitis induced by pegylated interferion-alpha-2b in a patient infected with genotype-1 hepatitis C virus\presentation of a case. Clin. Drug Investig. 25, 281-284 (2005). (Pubitemid 40593617)
44. Grossmann, S. D. C., Teixeira, R., de Aguiar, M. C F. & do Carmoa, M. A. V Exacerbation of oral lichen planus lesions during treatment of chronic hepatitis C with pegylated interferon and ribavirin. Eur. J. Gastroenterol. Hepatol. 20, 702-706 (2008).
45. Hashimoto, Y., Kanto, H. & Itoh, M. Adverse skin reactions due to pegylated interferon alpha 2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus. J. Dermatol. 34, 577-582 (2007). (Pubitemid 47228537)
46. Kartal, E. D., Alpat, S. N., Ozgunes, I. & Usluer, G. Reversible alopecia universalis secondary to PEG-interferon alpha-2b and ribavirin combination therapy in a patient with chronic hepatitis C virus infection. Eur. J. Gastroenterol. Hepatol. 19, 817-820 (2007). (Pubitemid 47266714)
47. Yurci, A. et al. Pyoderma gangrenosum and exacerbation of psoriasis resulting from pegylated interferon alpha and ribavirin treatment of chronic hepatitis C Eur. J. Gastroenterol. Hepatol. 19, 811-815 (2007). (Pubitemid 47266713)
48. Richetta, A. G. et al. Treatment of erythrodermic psoriasis in HCV+ patient with adalimumab. Dermatol. Ther. 22, S16-S18 (2009).
49. Veldt, B. J., Schalm, S. W. & Janssen, H. L. A. Severe allergic eczema due to pegylated alpha-interferon may abate after switching to daily conventional alpha-interferon. J. Clin. Gastroenterol. 41, 432 (2007). (Pubitemid 46573076)
50. Constant, A. et al. Mood alterations during interferon-alfa therapy in patients with chronic hepatitis C: evidence for an overlap between manic/hypomanic and depressive symptoms. J. Clin. Psychiatry 66, 1050-1057 (2005). (Pubitemid 41191799)
51. Raison, C L., Demetrashvili, M., Capuron, L. & Miller, A. H. Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs 19, 105-123 (2005). (Pubitemid 40321763)
52. Renault, P F et al. Psychiatric complications of ong-term interferon alfa therapy. Arch. Intern. Med. 147, 1577-1580 (1987). (Pubitemid 17138838)
53. Shafer, M. Management of side effects of interferon alfa and ribavirin-based treatment of chronic hepatitis C: Psychiatric side effects. Hot Topics In Viral Hepatitis 9, 11-20 (2008).
54. Huckans, M. et al. Antiviral therapy completion and response rates among hepatitis C patients with and without schizophrenia. Schizophr. Bull. 36, 165-172 (2010).
55. Schaefer, M. et al. Hepatitis C treatment in "difficult-to- treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. Hepatology 46, 991-998 (2007). (Pubitemid 350144763)
56. Chainuvati, S. et al. Comparison of hepatitis C treatment patterns in patients with and without psychiatric and/or substance use disorders. J. Viral Hepat 13, 235-241 (2006).
57. Sherman, M. et al. Management of chronic hepatitis C: consensus guidelines. Can. J. Gastroenterol. 21 (Suppl. C), 25C-34C (2007). (Pubitemid 47177083)
58. NCBI. Center for Epidemiologic Studies Depression Scale (CES-D) US Library of Medicine NIH [online] http://www.ncbi.nlm. nih.gov/books/NBK26257 2011).
59. Mistler, L. A. et al. Hepatitis C treatment for people with severe mental illness. Psychosomatics 47, 93-107 (2006). (Pubitemid 43346956)
60. Wayne, P. & Healey, K. in The physicians' desk reference: hepatitis C management guide 117-150 (Thompson, Montvale, 2005).
61. Nickel, T., Sonntag, A., Backmund, M. & Pollmacher, T. Depression during therapy with interferon alpha\how long should an antidepressant treatment last? Pharmacopsychiatry 38, 102-104 (2005). (Pubitemid 40388793)
62. Dove, L. M. et al. Decline in male sexual desire, function, and satisfaction during and after antiviral therapy for chronic hepatitis C Gastroenterology 137, 873-884 (2009).
63. Sleijfer, S. et al. Side effects of interferon-alpha therapy. Pharm. World Sci. 27, 423-431 (2005).
64. Cooper, C L., Al-Bedwawi, S., Lee, C & Garber, G. Rate of infectious complications during interferon-based therapy for hepatitis C is not related to neutropenia. Clin. Infect Dis. 42, 1674-1678 (2006). (Pubitemid 43839429)
65. Roomer, R., Hansen, B. E., Janssen, H. L. & de Knegt, R. J. Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C Hepatology 52, 1225-1231 (2010).
66. Cooper, C L. & Al-Bedwawi, S. Infection rates in HIV-HCV patients treated with interferon are similar to those in HCV mono-infection and not related to neutropenia. HIV Clin. Trials 7, 251-254 (2006). (Pubitemid 44963809)
67. Thompson, A. J. & Lummis, S. C R. The 5-HT3 receptor as a therapeutic target. Expert Opin. Ther. Targets 11, 527-540 (2007).
68. Costiniuk, C T., Mills, E. & Cooper, C L. Evaluation of oral cannabinoid-containing medications for the management of interferon and ribavirin-induced anorexia, nausea and weight loss in patients treated for chronic hepatitis C virus. Can. J. Gastroenterol. 22, 376-380 (2008). (Pubitemid 351772331)
69. Cappell, M. S. Colonic toxicity of administered drugs and chemicals. Am. J. Gastroenterol. 99, 1175-1190 (2004). (Pubitemid 38917825)
70. Tada, H. et al. Ischemic colitis during interferon-alpha treatment for chronic active hepatitis C J. Gastroenterol. 31, 582-584 (1996). (Pubitemid 26288430)
71. Salcedo-Mora, X. et al. Chronic hepatitis C and Crohn's disease: nosocomial infection treatment with PEG-interferon plus ribavirin. Digestion 73, 210-214 (2006). (Pubitemid 44448881)
72. Scherzer, T. M. et al. Efficacy and safety of antiviral therapy in patients with Crohn's disease and chronic hepatitis C Aliment Pharmacol. Ther. 28, 742-748 (2008).
73. Nadeem, A. et al. Effects of combined interferon alpha and ribavirin therapy on thyroid functions in patients with chronic hepatitis C J. Coll. Physicians Surg. Pak. 19, 86-89 (2009).
74. Tran, H. A., Jones, T. L. & Batey, R. G. The spectrum of thyroid dysfunction in an Australian hepatitis C population treated with combination Interferon-alpha2beta and Ribavirin. BMC Endocr. Disord. 5, 8 (2005).
75. Tomer, Y., Blackard, J. T & Akeno, N. Interferon alpha treatment and thyroid dysfunction. Endocrinol. Metab. Clin. North Am. 36, 1051-1066 (2007). (Pubitemid 350026253)
76. Lunel, F. & Cacoub, P Treatment of autoimmune and extrahepatic manifestations of hepatitis C virus infection. J. Hepatol. 31 (Suppl. 1), 210-216 (1999). (Pubitemid 30002721)
77. Manns, M. P & Rambusch, E. G. Autoimmunity and extrahepatic manifestations in hepatitis C virus infection. J. Hepatol. 31 (Suppl. 1), 39-42 (1999). (Pubitemid 30002689)
78. Prummel, M. F. & Laurberg, P Interferon-alpha and autoimmune thyroid disease. Thyroid 13, 547-551 (2003).
79. Mazziotti, G. et al. Temporal relationship between the appearance of thyroid autoantibodies and development of destructive thyroiditis in patients undergoing treatment with two different type-1 interferons for HCV-related chronic hepatitis: a prospective study J. Endocrinol. Invest 25, 624-630 (2002). (Pubitemid 34784743)
80. Rodriguez-Torres, M. et al. Thyroid dysfunction (TD) among chronic hepatitis C patients with mild and severe hepatic fibrosis. Ann. Hepatol. 7, 72-77 (2008). (Pubitemid 351468541)
81. Tarantino, G., Gagliardi, G. & Conca, P Do thyroid abnormalities detected in patients treated for HCV-related chronic hepatitis persist? Int. J. Immunopathol. Pharmacol. 21, 467-469 (2008). (Pubitemid 351988413)
82. Marcellin, P. et al. Sustained hypothyroidism induced by recombinant alpha interferon in patients with chronic hepatitis C Gut 33, 855-856 (1992).
83. Benelhadj, S. et al. Incidence of dysthyroidism during interferon therapy in chronic hepatitis C Horm. Res. 48, 209-214 (1997). (Pubitemid 27462381)
84. Baudin, E. et al. Reversibility of thyroid dysfunction induced by recombinant alpha-interferon in chronic hepatitis C Clin. Endocrinol. 39, 657-661 (1993). (Pubitemid 24010954)
85. Schreuder, T. C et al. High incidence of type 1 diabetes mellitus during or shortly after treatment with pegylated interferon alpha for chronic hepatitis C virus infection. Liver Int. 28, 39-46 (2008).
86. Fabris, P et al. Type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy. Aliment Pharmacol. Ther. 18, 549-558 (2003). (Pubitemid 37186604)
87. Niewold, T B. & Swedler, W. I. Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis C Clin. Rheumatol. 24, 178-181 (2005). (Pubitemid 40552976)
88. Olivieri, I., Palazzi, C & Padula, A. Hepatitis C virus and arthritis. Rheum. Dis. Clin. North Am. 29, 111-122 (2003). (Pubitemid 36298106)
89. Wilson, L E., Widman, D., Dikman, S. H. & Gorevic, P D. Autoimmune disease complicating antiviral therapy for hepatitis C virus infection. Semin. Arthritis Rheum. 32, 163-173 (2002). (Pubitemid 36043715)
90. Saadoun, D. et al. Antiviral therapy for hepatitis C virus-associated mixed cryoglobulinemia vasculitis: a long-term followup study. Arthritis Rheum. 54, 3696-3706 (2006). (Pubitemid 44737183)
91. Yamamoto, T., Katayama, I. & Nishioka, K. Psoriasis and hepatitis C virus. Acta Derm. Venereol. 75, 482-483 (1995). (Pubitemid 26051892)
92. Akamatsu, S. et al. Immune thrombocytopenia during interferon-alfa therapy for renal cel carcinoma. Hinyokika Kiyo 52, 789-792 (2006). (Pubitemid 44787774)
93. McHutchison, J. G. et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C Hepatitis Interventional Therapy Group. N. Engl. J. Med. 339, 1485-1492 (1998).
94. Kumar, K. S. et al. Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C Am. J. Gastroenterol. 97, 2432-2440 (2002).
95. Kanazawa, H. & Yoshikawa, J. Accelerated decline in lung function and impaired reversibility with salbutamol in asthmatic patients with chronic hepatitis C virus infection: a 6-year follow-up study. Am. J. Med. 116, 749-752 (2004). (Pubitemid 38622311)
96. Hurst, E. A. & Mauro, T Sarcoidosis associated with pegylated interferon alfa and ribavirin treatment for chronic hepatitis C: a case report and review of the literature. Arch. Dermatol. 141, 865-868 (2005). (Pubitemid 41058068)
97. Goldberg, H. J. et al. Sarcoidosis after treatment with interferon-alpha: a case series and review of the literature. Respir. Med. 100, 2063-2068 (2006). (Pubitemid 44514945)
98. Wendling, J. et al. Sarcoidosis during combined interferon alfa and ribavirin therapy in 2 patients with chronic hepatitis C Arch. Dermatol. 138, 546-547 (2002). (Pubitemid 34290046)
99. Slavenburg, S., Heijdra, Y F. & Drenth, J. P. Pneumonitis as a consequence of (peg) interferon-ribavirin combination therapy for hepatitis C: a review of the literature. Dig. Dis. Sci. 55, 579-585 (2010).
100. Dhillon, S. et al. Irreversible pulmonary hypertension associated with the use of interferon alpha for chronic hepatitis C Dig. Dis. Sci. 55, 1785-1790 (2010).
101. Macedo, G. & Ribeiro, T. Interferon plus ribavirin: a cautionary note. Am. J. Gastroenterol. 94, 3087-3088 (1999). (Pubitemid 29482803)
102. Condat, B. et al. Fatal cardiomyopathy associated with pegylated interferon/ribavirin in a patient with chronic hepatitis C Eur. J. Gastroenterol. Hepatol. 18, 287-289 (2006).
103. Boonen, A., Stockbrugger, R. W. & van der Linden, S. Pericarditis after therapy with interferon-alpha for chronic hepatitis C Clin. Rheumatol. 18, 177-179 (1999). (Pubitemid 29223045)
104. Narkewicz, M. R. et al. Ophthalmologic complications in children with chronic hepatitis C treated with pegylated interferon. J. Pediatr. Gastroenterol. Nutr. 51, 183-186 (2010).
105. Cuthbertson, F M., Davies, M. & McKibbin, M. Is screening for interferon retinopathy in hepatitis C justified? Br. J. Ophthalmol. 88, 1518-1520 (2004). (Pubitemid 39573588)
106. Kim, E. T., Kim, L H., Lee, J. I. & Chin, H. S. Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin. Jpn J. Ophthalmol. 53, 598-602 (2009).
107. Lim, J. W. & Shin, M. C Pegylated-interferon-associated retinopathy in chronic hepatitis patients. Ophthalmologica 224, 224-229 (2010).